Trials / Terminated
TerminatedNCT00994214
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIM 23A760 | Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2009-10-14
- Last updated
- 2019-11-22
- Results posted
- 2016-02-10
Locations
23 sites across 13 countries: United States, Belgium, Brazil, Czechia, France, Latvia, Lithuania, Mexico, Netherlands, Poland, Romania, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT00994214. Inclusion in this directory is not an endorsement.